Belantamab Mafodotin
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
What will happen during the trial?
This is a phase I dose escalation and expansion study in RMM and RRMM followed by a single arm phase II expansion in high risk, NDMM. The phase I portion of the protocol will utilize a standard 3+3 dose escalation design to determine the maximum tolerated dose (MTD) and RP2D of the KRd-belantamab mafodotin combination. The phase II portion of the trial is a two-stage design that will assess the efficacy and safety of the combination in newly diagnosed, high-risk MM patients.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 70 patients (estimated)
- Sponsors
- Atrium Health's Levine Cancer Institute - Charlotte (Main)
- Collaborators
- Amgen, GlaxoSmithKline
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), High Risk
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1159
- NCT Identifier
- NCT04822337
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.